Tigecycline: what is it, and where should it be used?

Livermore, David M ORCID: https://orcid.org/0000-0002-9856-3703 (2005) Tigecycline: what is it, and where should it be used? Journal of Antimicrobial Chemotherapy, 56 (4). pp. 611-614. ISSN 0305-7453

Full text not available from this repository. (Request a copy)

Abstract

Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials with activity against Gram-negative bacteria. It evades acquired efflux and target-mediated resistance to classical tetracyclines, but not chromosomal efflux in Proteeae and Pseudomonas. Cmax+ is low, but tissue penetration is excellent and the compound has shown equivalence to imipenem/cilastatin in intra-abdominal infection and to vancomycin plus aztreonam in skin and skin structure infection. Tigecycline may prove particularly useful for treatment of surgical wound infections, where both gut organisms and MRSA are likely pathogens. It is also likely to find a role in the treatment of infections due to multiresistant pathogens, including Acinetobacter spp. and ESBL producers, as well as MRSA and enterococci.

Item Type:	Article
Uncontrolled Keywords:	anti-bacterial agents,bacterial infections,drug resistance, bacterial,humans,minocycline,molecular structure
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	Rhiannon Harvey
Date Deposited:	11 Jul 2011 11:28
Last Modified:	27 Feb 2023 17:31
URI:	https://ueaeprints.uea.ac.uk/id/eprint/33495
DOI:	10.1093/jac/dki291

Actions (login required)

View Item